Our client sought to demystify the development and ambitions of CAR-T developers in China to understand each player’s competitive strength; the threat that they pose to the US & EU markets, and the challenges and opportunities for clinical development in partnership.
Eradigm’s thorough landscape assessment characterised Chinese developers by their ambition; clinical development stage and existing western collaborations to deliver strategic insight of how key competitors have played to date, the most significant risks to monitor and the avenues of opportunity.
